Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

912 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.
Gautam R, Nishimura Y, Lee WR, Donau O, Buckler-White A, Shingai M, Sadjadpour R, Schmidt SD, LaBranche CC, Keele BF, Montefiori D, Mascola JR, Martin MA. Gautam R, et al. Among authors: lee wr. J Virol. 2012 Aug;86(16):8516-26. doi: 10.1128/JVI.00644-12. Epub 2012 May 30. J Virol. 2012. PMID: 22647691 Free PMC article.
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Kubo M, Nishimura Y, Shingai M, Lee W, Brenchley J, Lafont B, Buckler-White A, Igarashi T, Martin MA. Kubo M, et al. J Virol. 2009 Jul;83(14):7099-108. doi: 10.1128/JVI.02522-08. Epub 2009 May 6. J Virol. 2009. PMID: 19420078 Free PMC article.
Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.
Shingai M, Donau OK, Schmidt SD, Gautam R, Plishka RJ, Buckler-White A, Sadjadpour R, Lee WR, LaBranche CC, Montefiori DC, Mascola JR, Nishimura Y, Martin MA. Shingai M, et al. Among authors: lee wr. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19769-74. doi: 10.1073/pnas.1217443109. Epub 2012 Nov 5. Proc Natl Acad Sci U S A. 2012. PMID: 23129652 Free PMC article.
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza D, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Rodgers JP, Sandler HM. Lee WR, et al. J Clin Oncol. 2024 May 17:JCO2302445. doi: 10.1200/JCO.23.02445. Online ahead of print. J Clin Oncol. 2024. PMID: 38759121
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.
Fecteau RE, Koontz BF, Hoffman KE, Halabi S, Howard LE, Anand M, George DJ, Zhang T, Berry WR, Lee WR, Harrison MR, Corn PG, Armstrong AJ. Fecteau RE, et al. Among authors: lee wr. Prostate Cancer Prostatic Dis. 2024 Feb 22. doi: 10.1038/s41391-024-00811-5. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38388778
912 results